Introduction
Angiogenesis is an important step in the development of cancer and is necessary for primary tumor growth, invasiveness, and metastasis. [1] Vascular endothelial growth factor (VEGF-c) is believed to be important for the process of initiation of angiogenesis and is a major mediator of breast cancer angiogenesis. [2] Overexpression of VEGF-c has been shown in various cancers. [3] Several polymorphisms in the VEGF-c gene have been reported to affect the expression of the gene. The 2578CC, 2549 del/del, 1154GG, and 634CC have been shown associated with a higher VEGF-c production, [4] [5] [6] [7] whereas the +936 T allele has been shown to correlate with lower VEGF plasma levels. [8, 9] In addition, the 634G/C polymorphism is located within a potential binding site of the MZF1 transcription factor [10] and the +936C/T polymorphism leads to a loss of a potential AP-4 binding site. [8, 9] Recent studies have shown that some VEGF-c polymorphisms are associated with the development of cancer. The 1154AA genotype, for example, is associated with a decreased prostate cancer risk and less advanced melanomas [11, 12] and the +936 C/T polymorphism with a decreased breast cancer risk. [9] In breast cancer, VEGF-c has been shown to be of prognostic importance. [13] These data suggest that the polymorphisms involved in the angiogenic pathway may affect the progression or aggressiveness of the tumor, including breast tumors. In the present study, we investigated the relationship between genetic polymorphism in the VEGF-c gene and the development of breast cancer in patients from Kanpur and adjacent areas. Polymorphisms were are shown in Table 2 . Altogether, only 2 of 75 breast cancer cases had distant metastasis indicating that even the prevalent cases were recruited relatively shortly after diagnosis, excluding biases due to preferential survival. After DNA digestion, the coded samples were divided on the plates by randomly mixing cases and controls.
Polymerase chain reaction (PCR) amplification
The primer sequence for the polymorphism of VEGF-c gene (+936 C/T) was retrieved from the Ensemble database. Primers were designed for the regions around the polymorphic sites/or for the entire coding regions with the help of the primer blast tool of the NCBI or Gene tool software. Primers were custom synthesized by Micelles Life Sciences, Lucknow, India.
Restriction fragment length polymorphism (RFLP) analysis
The +936C/T polymorphism was analyzed in the sample sets using RFLP analysis. The assays were set up after PCR as described. [16] PCR products were digested with restriction endonucleases, using the buffers and temperatures recommended by the manufacturers. The digested PCR products were resolved on a 10% polyacrylamide gel and stained with ethidium bromide for visualization under ultraviolet light.
Statistical analysis
Genotype data of control samples for polymorphism were analyzed for fitness in the Hardy-Weinberg equilibrium using the online calculator. [23] Chi-square test was used to compare genotype data between cases and controls using Vassar stats online calculator, [24, 25] adopting dominant, recessive, codominant, and additive models. P < 0.05 was considered statistically significant.
The differences in the genotype and haplotype frequencies of the studied polymorphism in the breast cancer cases and controls were compared for statistical significance by the Yates corrected Chi-square test. Odds ratios and 95% confidence intervals were calculated for associations of genotypic polymorphism between breast cancer cases and healthy controls.
Results
We examined the effect of polymorphism in the VEGF-c gene on breast cancer development [ Figure 1 ]. The polymorphism +936C/T were examined in breast cancer samples and controls using the RFLP assay. The genotype distribution of studied polymorphism followed the Hardy-Weinberg equilibrium in every sample set. The genotype and allele distributions among the breast cancer cases and control subjects are shown in Table 1 . The number of samples analyzed for polymorphism was not exactly equal because of unsuccessful amplification of a few samples. No differences in the allele or genotype frequencies between the breast cancer cases and controls were detected in the population. The lack of association remained when the data were stratified by age (data not shown). Haplotypes were created using genotyping data of the polymorphism +936C/T. No significant differences in haplotype frequencies between the breast cancer cases and controls were detected. There were no indications that the polymorphism would have any effects on the other tumor characteristics. The addition of the information of the +936C/T polymorphism data did not change the results (data not shown).
Discussion
Functional polymorphisms, which have an effect on the regulation of gene expression, can contribute to the differences between individuals in susceptibility to and severity of a disease. The effect may be seen by a polymorphism alone, or in combination with other polymorphisms. Several studies have shown that polymorphisms in the promoter as well as in the 5' and 3' untranslated regions of the VEGF-c gene are associated with the production of the VEGF-c protein. [4] [5] [6] [7] [8] [9] [10] We analyzed the +936(C/T) polymorphism using RFLP assay. The allele and genotype distributions of the polymorphism were in close agreement with those previously published for healthy Caucasian individuals. [8, 11, 12, [15] [16] [17] [18] [19] [20] [21] [22] In a previous study among 500 Caucasian breast cancer cases and 500 controls, Krippl et al. have shown a decreased risk of breast cancer in individuals who were +936 T allele carriers. [9] However, the genotypes in patients did not follow the Hardy-Weinberg equilibrium. In another study, no association between the +936(C/T) polymorphism and risk to breast cancer among 862 cases and 713 controls could be observed. [21] Here, we did a case-control study of 75 women with breast cancer. We observed no differences in the allele or genotype frequencies between breast cancer case and control groups, (odds ratio, 1.26; 95% confidence interval, 0.50-1.00; P = 0.715). To the best of our knowledge, no other studies on the effect of the other polymorphisms on the risk of breast cancer have been published in Indian population. In this study, no significant Figure 1 : Structure of the vascular endothelial growth factor gene indicating the polymorphism included in the present study differences in the allele, genotype, or haplotype distribution of the polymorphism in the VEGF-c gene between breast cancer cases and respective controls were detected. Being the only Indian study thus far, our study provided strong evidence that the +936 C/T allele polymorphism do not modify the risk of breast cancer. This result is not surprising, because VEGF-c, as a key mediator of angiogenesis, is more likely to alter the aggressiveness of the tumor than susceptibility to cancer. In summary, the present study investigated polymorphism in the VEGF-c gene in a case-control study. Our study provided evidence that the +936C/T polymorphism is not associated with breast cancer risk. However, some genotypes and haplotypes in the VEGF-c gene may have an effect on breast tumor growth. Functional studies of the haplotypes and an independent study are needed to confirm our results. The polymorphisms should also be studied in relation to metastasis and survival and whether they influence therapeutic effects. 
